Rohto Pharmaceutical Co (JP:4527) has released an update.
Rohto Pharmaceutical Co. reports a significant sales increase in the first quarter of FY3/2025, spurred by the lifting of pandemic restrictions and a weaker yen, leading to higher operating and ordinary profits. However, net income fell due to extraordinary losses. The company saw growth across domestic, Asian, European, and American markets, with an upward revision of the full-year forecast and an increased annual dividend from 30 yen to 33 yen.
For further insights into JP:4527 stock, check out TipRanks’ Stock Analysis page.
